Disclosed herein are compounds for use as antimicrobial agents, having a structure of formula (I): ##STR00001##

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

A resin containing a desirable compound is extracted from plant material and dissolved in a volatile non-polar solvent. The solvent is evaporated, cooling the solution and increasing the saturation level of the compound in the solution. A second volatile non-polar solvent, in which the compound is less soluble, is then added to the solution and evaporated. This again cools the solution and increases the saturation level until the compound has started to crystallize. The crystals are then filtered and rinsed. Crystallization is more rapid compared to traditional techniques. The resin is obtained from the plant material using an extraction solvent to form a solution, which is then floated above an immiscible liquid, where it is drawn off through a screen and the extraction solvent evaporated.

A resin containing a desirable compound is extracted from plant material and dissolved in a volatile non-polar solvent. The solvent is evaporated, cooling the solution and increasing the saturation level of the compound in the solution. A second volatile non-polar solvent, in which the compound is less soluble, is then added to the solution and evaporated. This again cools the solution and increases the saturation level until the compound has started to crystallize. The crystals are then filtered and rinsed. Crystallization is more rapid compared to traditional techniques. The resin is obtained from the plant material using an extraction solvent to form a solution, which is then floated above an immiscible liquid, where it is drawn off through a screen and the extraction solvent evaporated.